STERIS plc (NYSE:STE – Get Free Report) declared a quarterly dividend on Tuesday, January 28th,RTT News reports. Shareholders of record on Thursday, February 20th will be paid a dividend of 0.57 per share by the medical equipment provider on Friday, March 21st. This represents a $2.28 annualized dividend and a yield of 1.03%.
STERIS has increased its dividend by an average of 9.5% annually over the last three years. STERIS has a payout ratio of 20.9% indicating that its dividend is sufficiently covered by earnings. Analysts expect STERIS to earn $10.05 per share next year, which means the company should continue to be able to cover its $2.28 annual dividend with an expected future payout ratio of 22.7%.
STERIS Stock Performance
NYSE STE traded down $0.54 during trading hours on Tuesday, hitting $221.28. 359,733 shares of the stock were exchanged, compared to its average volume of 459,130. STERIS has a 12-month low of $197.82 and a 12-month high of $248.24. The stock has a 50-day moving average of $211.46 and a 200 day moving average of $224.77. The company has a market cap of $21.84 billion, a price-to-earnings ratio of 50.52 and a beta of 0.84. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33.
Wall Street Analyst Weigh In
STE has been the topic of several recent research reports. StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. Piper Sandler raised STERIS from a “neutral” rating to an “overweight” rating and upped their target price for the company from $230.00 to $260.00 in a research note on Thursday, October 24th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Friday, November 8th. JMP Securities restated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research report on Monday, November 18th. Finally, Stephens reiterated an “overweight” rating and set a $260.00 price objective on shares of STERIS in a research report on Thursday, November 7th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, STERIS has a consensus rating of “Moderate Buy” and an average price target of $262.50.
Check Out Our Latest Report on STERIS
Insider Buying and Selling at STERIS
In other news, SVP Cary L. Majors sold 1,682 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the transaction, the senior vice president now owns 11,372 shares in the company, valued at approximately $2,471,363.04. This represents a 12.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.14% of the stock is currently owned by corporate insiders.
STERIS Company Profile
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
See Also
- Five stocks we like better than STERIS
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- How to Calculate Inflation Rate
- What Does the Future Hold for Eli Lilly?
- Options Trading – Understanding Strike Price
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.